Recombinant Human TrkB Protein

重组人TrkB蛋白 | 重组人类 TrkB 蛋白

BDNF/NT-3 growth factors receptor | EC 2.7.10 | EC 2.7.10.1 | GP145-TrkB | Neurotrophic tyrosine kinase receptor type 2 | neurotrophic tyrosine kinase, receptor, type 2 | NTRK2 | TrkB tyrosine kinase | TrkB | trk-B | TRKBBDNF-tropomyosine receptor kinase

rp181612-50μg

50μg

无动物源

≥95%(SDS-PAGE)

Purity: ≥95%, by SDS-PAGE visualized with Coomassie® Blue Staining. Description： The neurotrophins, including NGF, BDNF, NT-3, and NT-4/5, constitute a group of structurally related, secreted proteins that play an important role in the development and function of the nervous system. The biological activities of the neurotrophins are mediated by binding to different members of the Trk family tyrosine kinase receptors. Three Trk family proteins, TrkA, TrkB, and TrkC, exhibiting different ligand specificities, have been identified. TrkA binds NGF, TrkB binds BDNF and NT‑4/5, and TrkC binds NT-3. All Trk family proteins share a conserved complex subdomain organization consisting of a signal peptide, two cysteine-rich domains, a cluster of three leucine-rich motifs, and two immunoglobulin-like domains in the extracellular region, as well as an intracellular region that contains the tyrosine kinase domain. Natural splice variants of the different Trks, including TrkB variants lacking the first cysteine-rich domain, the first and second or all three of the leucine-rich motifs, or the tyrosine kinase domain, have been described. The role of the different extracellular subdomains of TrkB in mediating neurotrophin binding and discrimination is currently being investigated. At the protein sequence level, human and rat TrkB are greater than 90% identical and the proteins exhibit cross-species activity. TrkB is primarily expressed in the nervous system. However, low levels of TrkB expression have also been observed in a wide variety of tissues (pancreas, kidneys, ovary) outside the nervous system.

Immobilized Recombinant Human TrkB Protein (rp181612) at 1.0 μg/mL can bind Rinat patent anti-TrkB (anti-TrkB) (Ab209857) with the EC50 of 34.2 ng/mL.

重组表达

45.0 kDa

C-His

54.2-80.0 kDa, under reducing conditions; 49.9-74.0 kDa, under non-reducing conditions

HEK293 Accession #: Q16620 | HEK293

<1.0 EU/μg

人(Human)

1-430 aa

MSSWIRWHGPAMARLWGFCWLVVGFWRAAFACPTSCKCSASRIWCSDPSPGIVAFPRLEPNSVDPENITEIFIANQKRLEIINEDDVEAYVGLRNLTIVDSGLKFVAHKAFLKNSNLQHINFTRNKLTSLSRKHFRHLDLSELILVGNPFTCSCDIMWIKTLQEAKSSPDTQDLYCLNESSKNIPLANLQIPNCGLPSANLAAPNLTVEEGKSITLSCSVAGDPVPNMYWDVGNLVSKHMNETSHTQGSLRITNISSDDSGKQISCVAENLVGEDQDSVNLTVHFAPTITFLESPTSDHHWCIPFTVKGNPKPALQWFYNGAILNESKYICTKIHVTNHTEYHGCLQLDNPTHMNNGDYTLIAKNEYGKDEKQISAHFMGWPGIDDGANPNYPDVIYEDYGTAANDIGDTTNRSNEIPSTDVTDKTGREHHHHHHH

Yes

Yes